We investigated the effectiveness of fractional carbon dioxide laser (FCO 2) vs fractional radiofrequency (FRF) and FCO 2 vs FRF plus FCO 2 combination in the treatment of acne scars. Twenty-seven patients were included. Scar severity was scored with "Echelle d'évaluation clinique des cicatrices d'acné" (ECCA) by a dermatologist blinded to treatment. FCO 2 and FRF were administered to the right and left halves of the patients' faces, respectively, at the first three visits, once a month. At the fourth visit, FCO 2 was administered to both sides. Last evaluation was performed 6 months

Actinic lichen planus (ALP) that affects sun-exposed areas of the skin is an uncommon variant of lichen planus. While ALP is commonly triggered by ultraviolet radiation exposure, genetic predisposition may also be important in the pathogenesis of the disease. Herein, we report three patients with ALP from the same family, which supports the genetic etiopathogenetic factors of ALP.

Makale bilim dalı: Dermatoloji Makale başlığı: Eroziv plantar liken planus: olağan bir hastalığın nadir klinik varyantı. Kısa başlık: Eroziv plantar liken planus olgusu. Özet: Liken planus sık görülen mukoza ve deriyi tutan inflamatuar bir hastalıktır. Liken planus insidansı %0,1-4'tür. Palmoplantar liken planus ise hastalığın nadir görülen bir variantıdır. Palmoplantar liken planus'un birçok klinik formu vardır. Eroziv veya ülseratif

The aim of this study was to evaluate the response to IFN‐α2a treatment as monotherapy in stage IB patients with mycosis fungoides (MF) in second‐line therapy. Twenty‐five patients with recurrent or persistent MF were included in the study. The diagnosis of MF was established according to clinical and histopathological signs. Clinical staging was made using TNMB classification. IFN‐α2a as monotherapy was used as treatment. IFN‐α2a was administered at a dose of 3 x 106 units thrice a week subcutaneously as initially described. According to clinical tolerance, the dose was increased every 4 weeks to 6 – 9 x 106 units. IFN‐α2a was used more frequently for at least 3 months after complete remission. Treatment success was evaluated with Clinical Response (disappearance of all clinical evidence = Complete Remission [CR], ≥50% decrease in extent or severity = Partial Remission [PR], unresponsiveness to treatment = Stable Disease [SD], progression of MF = Progressive Disease [PD]). The average age was 51.3 ± 9.1. CR and PR were achieved in 11 (44%) and 12 (48%) patients, respectively. PD was observed in two (8%) patients. CR was accomplished at 16.1 ± 9.8 weeks. Recurrences were mostly observed within 1 year (10.4 ± 7.7 months). The recurrence rate was 45.4%. The mean duration of CR was 33.3 ± 7.9 months. Side effects were seen in 36% of the patients (18.2% in CR). The most common side effect was fatigue (12%). The patients received 11 different types of treatment before IFN‐α2a treatment. The most frequent therapy prior to IFN‐α2a treatment was narrow‐band ultraviolet‐B (NB‐UVB) phototherapy (15 [60%] patients). CR can be achieved in a relatively short period of time in patients receiving IFN‐α2a in MF. The duration of CR is reasonable. The side effects of IFN‐α2a are acceptable. Therefore, IFN‐α2a as monotherapy is a good option in stage IB second‐line MF therapy.

No abstract